Literature DB >> 10583602

Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.

K Vandenborre1, S W Van Gool, A Kasran, J L Ceuppens, M A Boogaerts, P Vandenberghe.   

Abstract

Occupancy of CTLA-4 (cytotoxic T-lymphocyte antigen-4 or CD152) negatively regulates the activation of mouse T lymphocytes, as indicated by the fate of CTLA-4-deficient mice, by the impact of anti-CTLA-4 monoclonal antibodies (mAbs) on mouse T-cell activation in vitro and by the impact of CTLA-4 blockade on the course of experimental tumoral, autoimmune, alloimmune or infectious disease in this animal. The function of human CTLA-4, however, remains less clear. The expression and function of human CTLA-4 were further explored. CTLA-4 was expressed under mitogenic conditions only, its expression being, at least partially, dependent on the secretion of interleukin-2. Memory T cells expressed CTLA-4 with faster kinetics than naive T cells. The functional role of human CTLA-4 was assessed utilizing a panel of four anti-CTLA-4 mAbs that blocked the interaction between CTLA-4 and its ligands. These mAbs, in immobilized form, profoundly inhibited the activation of T cells by immobilized anti-CD3 mAb in the absence of anti-CD28 mAb, but co-stimulated T-cell activation in the presence of anti-CD28 mAb. Finally, and importantly, blockade of the interaction of CTLA-4 with its ligands using soluble anti-CTLA-4 mAbs, in intact form or as Fab fragments, enhanced T-cell activation in several polyclonal or alloantigen-specific CD80- or CD80/CD86-dependent assays, as measured by cytokine production, cellular proliferation or cytotoxic responses. It is concluded that interaction of CTLA-4 with its functional ligands, CD80 or CD86, can down-regulate human T-cell responses, probably by intracellular signalling events and independent of CD28 occupancy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583602      PMCID: PMC2326945          DOI: 10.1046/j.1365-2567.1999.00888.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  CTLA4 mediates antigen-specific apoptosis of human T cells.

Authors:  J G Gribben; G J Freeman; V A Boussiotis; P Rennert; C L Jellis; E Greenfield; M Barber; V A Restivo; X Ke; G S Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

2.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

3.  Effects of anti-IL-4 receptor monoclonal antibody on in vitro T cell cytokine levels: IL-4 production by T cells from non-atopic donors.

Authors:  D M Bullens; A Kasran; X Peng; K Lorré; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

4.  Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: evidence for signal transduction through CD5.

Authors:  P Vandenberghe; J L Ceuppens
Journal:  Eur J Immunol       Date:  1991-02       Impact factor: 5.532

5.  Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T-cell activation.

Authors:  S W Van Gool; J L Ceuppens; H Walter; M de Boer
Journal:  Blood       Date:  1994-01-01       Impact factor: 22.113

6.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

7.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.

Authors:  P S Linsley; J L Greene; W Brady; J Bajorath; J A Ledbetter; R Peach
Journal:  Immunity       Date:  1994-12       Impact factor: 31.745

8.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

Review 9.  The B7 and CD28 receptor families.

Authors:  C H June; J A Bluestone; L M Nadler; C B Thompson
Journal:  Immunol Today       Date:  1994-07

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  23 in total

Review 1.  From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era.

Authors:  Alan G Baxter; Margaret A Jordan
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 2.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

3.  Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.

Authors:  Heather M Gibson; Carrie J Hedgcock; Barbara M Aufiero; Adam J Wilson; Mikehl S Hafner; George C Tsokos; Henry K Wong
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

4.  Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity.

Authors:  S Yamada; K Shinozaki; K Agematsu
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

5.  Prostaglandin E2-Induced Immune Suppression via Cytotoxic T-Lymphocyte Antigen 4 in Paratuberculosis.

Authors:  Yamato Sajiki; Satoru Konnai; Kei Watari; Tomohiro Okagawa; Akina Tanaka; Satoko Kawaji; Reiko Nagata; Naoya Maekawa; Yasuhiko Suzuki; Yukinari Kato; Shiro Murata; Yasuyuki Mori; Kazuhiko Ohashi
Journal:  Infect Immun       Date:  2022-09-14       Impact factor: 3.609

6.  Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy.

Authors:  Hideto Nakajima; Ayami Takayama; Takumi Ito; Tetsushi Yoshikawa
Journal:  BMJ Case Rep       Date:  2013-05-09

7.  Literature mining for the discovery of hidden connections between drugs, genes and diseases.

Authors:  Raoul Frijters; Marianne van Vugt; Ruben Smeets; René van Schaik; Jacob de Vlieg; Wynand Alkema
Journal:  PLoS Comput Biol       Date:  2010-09-23       Impact factor: 4.475

8.  Current evidence on the cytotoxic T-lymphocyte antigen 4 + 49G > A polymorphism and digestive system cancer risks: a meta-analysis involving 11,923 subjects.

Authors:  Liu Xiaolei; Yang Baohong; Ren Haipeng; Liu Shuzhen; Gao Jianfeng; Pan Xiangpo; Liu Haiyu; Yu Yuan; Zheng Dejie; Yang Jinhong; Wang Huanxin; Wang Wenhui; Yu Guohua
Journal:  Meta Gene       Date:  2015-10-22

9.  Lack of association between cytotoxic T-lymphocyte antigen 4 (CTLA-4) -1722T/C (rs733618) polymorphism and cancer risk: from a case-control study to a meta-analysis.

Authors:  Weifeng Tang; Hao Qiu; Heping Jiang; Bin Sun; Lixin Wang; Jun Yin; Haiyong Gu
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

10.  Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.

Authors:  Grégoire Wieërs; Nathalie Demotte; Danièle Godelaine; Pierre Van der Bruggen
Journal:  Cancers (Basel)       Date:  2011-07-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.